Janssen-Cilag International NV

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: Subsidiary

Employees: -

Market Cap: -

Website

Clinical Trials

An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

Phase 3

Completed

Conditions: Chronic Hepatitis C

Interventions: Drug: Telaprevir
Drug: Ribavirin
Drug: Pegylated-Interferon-alfa-2a

First Posted Date: 2012-01-20

Last Posted Date: 2016-05-05

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 163

Registration Number: NCT01513941

Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Conditions: Hepatitis C

First Posted Date: 2012-01-11

Last Posted Date: 2015-07-24

Lead Sponsor: Janssen-Cilag International NV

Registration Number: NCT01508286

Telaprevir Open-Label Study in Co-Infected Patients

Phase 3

Completed

Conditions: Hepatitis C, Chronic

Interventions: Drug: Telaprevir

First Posted Date: 2011-12-28

Last Posted Date: 2016-08-18

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 122

Registration Number: NCT01500616

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Phase 3

Completed

Conditions: Genotype 1 Chronic Hepatitis C

Interventions: Drug: Telaprevir
Drug: Pegylated-interferon-alfa-2a
Drug: Ribavirin

First Posted Date: 2011-12-23

Last Posted Date: 2015-01-30

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 36

Registration Number: NCT01498068

A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment

Phase 3

Completed

Conditions: Acquired Immunodeficiency Syndrome (AIDS) Virus
Human Immunodeficiency Virus (HIV) Infections

Interventions: Drug: Darunavir
Drug: Ritonavir

First Posted Date: 2011-10-07

Last Posted Date: 2017-11-27

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 274

Registration Number: NCT01448707

An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes

Phase 3

Completed

Conditions: Myelodysplastic Syndromes

First Posted Date: 2011-06-27

Last Posted Date: 2016-03-16

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 130

Registration Number: NCT01381809

A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CNTO 6785 1 mg/kg IV
Drug: CNTO 6785 3 mg/kg IV
Drug: Placebo IV
Drug: CNTO 6785 10 mg/kg IV
Drug: CNTO 6785 SC
Drug: Placebo SC

First Posted Date: 2011-02-02

Last Posted Date: 2013-01-28

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 32

Registration Number: NCT01288196

Velcade Consolidation Bone Study

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: bortezomib

First Posted Date: 2011-01-31

Last Posted Date: 2016-05-30

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 106

Registration Number: NCT01286077

Paliperidone Palmitate Flexible Dosing in Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Paliperidone Palmitate

First Posted Date: 2011-01-24

Last Posted Date: 2014-03-10

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 1044

Registration Number: NCT01281527

Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: paliperidone palmitate injection
Drug: oral antipsychotics

First Posted Date: 2010-03-05

Last Posted Date: 2015-02-18

Lead Sponsor: Janssen-Cilag International NV

Target Recruit Count: 769

Registration Number: NCT01081769

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy